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Abstract: Fructose ingestion is associated with the production of hepatic 
steatosis and hypertriglyceridaemia. For fructose to attain these effects 
in rats, simultaneous induction of fatty acid synthesis and inhibition of 
fatty acid oxidation is required. We aimed to determine the mechanism 
involved in the inhibition of fatty acid oxidation by fructose and 
whether this effect occurs also in human liver cells. Female rats were 
supplemented or not with liquid fructose (10% w/v) for 7 or 14 days; rat 
(FaO) and human (HepG2) hepatoma cells, and human hepatocytes were 
incubated with fructose 25 mM for 24 hours. The expression and activity 
of the enzymes and transcription factors relating to fatty acid beta-
oxidation were evaluated. Fructose inhibited the activity of fatty acid 
beta-oxidation only in livers of 14-day fructose-supplemented rats, as 
well as the expression and activity of  peroxisome proliferator activated 
receptor alpha (PPARalpha). Similar results were observed in FaO and 
ownregulation was not due to an 
osmotic effect or to an increase in protein-phosphatase 2A activity 
caused by fructose. Rather, it was related to increased content in liver 
of inactive, acetylated peroxisome proliferator activated receptor gamma 
coactivator 1alpha, due to a reduction in sirtuin 1 expression and 
activity. In conclusion, fructose inhibits liver fatty acid oxidation by 
reducing PPARalpha expression and activity, both in rat and human liver 
cells, by a mechanism involving sirtuin 1 down-regulation. 
 
Response to Reviewers: Reviewer #1:  
Major points: 
1. In order for the reader to comprehend the nutritional setting in 
which the changes are being observed, far more detail needs to be 
included to support/strengthen table 1.  Details on the nutritional 
content of the diet must be included (% calories from fat etc..). In the 
same sense, it would be useful to see the data presented as total 
calories consumed from diet vs fructose in drinking water.  
In this study the rats received a regular diet (Teklad Global 2018 Rodent 
Diet, fromHarlan Teklad), that provided 18% calories from fat, 24% from 
protein and 58% from carbohydrate. This information has been included in 
the new version of the manuscript (Materials and Methods section, pg 5, 
ln 22-23). 
Regarding the calories consumed from diet or from fructose, we calculated 
the data from the area under the curve of food or drink consumption in g 
or ml/days/cage (containing two rats). Our results are the following: 
 7days 14 days 
 Control Fructose Control Fructose 
Kcal from food 726.4 566.4 1609.6 1254.4 
Kcal from drink 0 338 0 798 
Total kcal 726.4 904.4 1609.6 2052.4 
 
As we already stated in our first version of the manuscript, “rats 
increased their calorie intake in a similar way at 7 (x1.24-fold) and 14 
days (x1.27-fold), mainly due to an increase in fructose calories (x1.37 
and x1.39-fold at 7 and 14 days, respectively), which was not compensated 
by a reduction in the ingestion of solid food”. Perhaps it was not clear 
enough, so we have rephrased the sentence (pg 11, ln  8-13): “rats 
increased their calorie intake in a similar way, from 726.4 to 904.4 
kcal/7days/2 rats (increase of 1.24-fold) and from 1609.6 to 2052.4  
kcal/14days/2 rats (x1.27-fold), at 7 and 14 days, respectively. The 
increase was mainly due to calories obtained from fructose, which 
represented a 37 and 39% of the total calories consumed at 7 and 14 days, 
respectively. This increase was not compensated by a sufficient reduction 
in the ingestion of solid food” 
2. The authors state that body weight changes were not observed, but 
the values should be included for the readers' benefit, and it would also 
be beneficial to know roughly what was happening in other key metabolic 
tissues, such as adipose tissue. For instance leptin levels increase 
significantly at 14 weeks, suggestive of an expansion of adipose tissue 
lipid content. One might postulate that in the face of impaired lipid 
oxidation, the liver is exporting more triglyceride in VLDL particles 
which are being taken up by the white fat. Basic histological examination 
of WAT and tissue weights would be good and examination measurement of 
key lipid handling genes even better. Likewise, analysis of lipid 
synthetic genes or genes regulating triglyceride release (MTP) in liver 
would be illuminating in this sense. The increased serum TG have to be 
coming from somewhere - and the data indicate that it is not from the 
diet. 
As the referee suggest, we have included body weight and white adipose 
tissue weight data in Table 1 of the new version of the manuscript. As 
can be seen in this table, there is no significant difference in total 
body weight (either expressed as area under the curve in g/7 or 14 
days/rat or as body weight at the end of treatment) between control and 
fructose groups.  Regarding adipose tissue weight, we neither observed 
statistically significant changes. On the other hand, plasma leptin 
levels are not significantly increased at 14 days 
Further, we already measured the expression of the genes involved in 
lipid synthesis, specifically liver-pyruvate kinase (L-PK), fatty acid 
synthase (FAS), stearoyl-CoA desaturase (SCD1), glycerol phosphate 
acyltransferase 1 (GPAT1) and acetyl-CoA carboxylase (ACC), and we found 
that fructose similarly induced their expression after 7- and 14-day 
supplementation (data in Table 2). Thus, serum and hepatic triglycerides 
come from the combined increase in lipid synthesis and reduction of fatty 
acid oxidation.  
Regarding additional experiments suggested by the referee, we did not 
perform basic histological examination of WAT at the moment of sacrifice. 
Nevertheless, we could determine the mRNA levels of MTP in hepatic 
samples from treated animals. Our results were: 
 7days 14 days 
 Control Fructose Control Fructose 
MTP 1 ± 0.14 1.21 ± 0.40 1 ±0.19 1.33 ± 0.33 
 
The lack of increase of MTP expression is not surprising, as MTP 
expression is regulated by reduced lipid availability, but an increase in 
the amount of lipids would not necessarily induce MTP expression. It 
would have been better to determine MTP activity, but this has to be 
performed in freshly obtained hepatic samples. 
3. Long chain fatty acid beta-oxidation is clearly impaired by 
fructose treatment, but is there any compensation via increased oxidation 
of short chain fatty acids? Are genes regulating fatty acid elongation 
down-regulated for instance? 
In our study we fed rats with a regular chow diet that did not provide 
short chain fatty acids (SCFA) but long chain fatty acids (LCFA: 
palmitic, stearic, oleic, linoleic and linolenic acids). SCFA could also 
be formed from colonic fermentation of dietary fiber, but the regular 
chow that we used in our study has a low amount of crude fiber (3.5%), 
and moreover, its consumption was reduced in fructose-supplemented 
animals. Thus, the bulk of fatty acids reaching the hepatic cells of the 
rats in our study are LCFA. In this case, SCFA could only derive from the 
β-oxidation of these LCFA, but as this is reduced in fructose-fed rats, 
the amount of SCFA formed should also be reduced. Therefore, if a 
compensatory response of increased SCFA oxidation existed, it would not 
result in a meaningful metabolic effect. 
Regarding fatty acid elongation, there are some reports showing that the 
expression of hepatic elongases (Elovl) might be controlled by several 
hormones and transcription factors, including PPARα, SREBP-1 and ChREBP 
(Wang et al., J Lipid Res. 2005, 46:706; Wang et al., J Lipid Res. 2006, 
47: 2028). It has been shown that carbohydrates induce hepatic Elovl-6 
along with L-PK and FAS through ChREBP (Wang et al., J Lipid Res. 2006, 
47:2028). Thus, as the referee suggested, we decided to determine the 
expression of hepatic Elovl-6 in hepatic samples from our control and 
fructose-supplemented rats. According to the general induction of genes 
involved in lipid synthesis, we also found a significant increase in 
Elovl6 expression at both 7 and 14 days. These results have been included 
in the text (pg 12, ln 4 and in Table 2).  
4. What effects are there on other key lipid-burning tissues? For 
instance what happens to beta-oxidative genes and UCP1 in the brown 
adipose tissue? This data would enable the specificity and relative 
contribution of the effects of fructose on hepatic lipid metabolism 
Unfortunately, we did not obtain brown adipose tissue (BAT) from the rats 
of our study. UCP-1 is a hallmark of BAT and under basal conditions it is 
not expressed in white adipose tissue (WAT). A recent report (Li et al, 
Gastroenterology, Epub ahead of print 2013 Oct 31, doi: 
10.1053/j.gastro.2013.10.059) showed that increased SIRT-1 activity 
increases the levels of the  hepatocyte-derived hormone fibroblast growth 
factor 21 (FGF21), and this enhanced energy expenditure through white fat 
“browning” (with increased expression in WAT of typical BAT genes such as 
UCP-1). However, in our study we detected a decrease, not an increase in 
SIRT-1 expression and activity. Moreover, we did not observe changes in 
the mRNA expression of hepatic FGF21 after 14 days of fructose 
supplementation (data not shown in the paper). Thus, hepatic FGF21 mRNA 
levels, expressed in arbitrary units were 1.00 ± 0.44 (control rats) and 
0.93 ± 0.27 (fructose-supplemented rats). These results suggest that UCP-
1 would not be expressed in WAT from fructose-supplemented animals. 
Minor points: 
1. The concept that mitochondrial long-chain fatty acid oxidation is 
impaired by fructose is not novel. In fact a paper from 1976 already 
demonstrates this effect and should at least be cited. (Prager GN, Ontko 
JA. Direct effects of fructose metabolism on fatty acid oxidation in a 
recombined rat liver mitochondria-high speed supernatant system. Biochim 
Biophys Acta. 1976 Mar 26;424(3):386-95.) 
According to the referee’s suggestion we have cited this reference in the 
novel version of the manuscript (pg 4 ln 15-16) 
2. Table one title should read "liver triglycerides". 
The spelling error has been corrected in the new version of the 
manuscript. 
3. Figure 6E does not appear to be discussed in the text? 
This was also an error, as Figure 6E corresponds to the levels of 
acetylated ChREBP protein in liver samples from control and 14-day 
fructose-supplemented rats, but in the text it was cited as 4E. This 
error has been corrected in the new version of the manuscript (pg 19, ln 
1). 
Reviewer #2 
General comments: 
This is a short manuscript. The rationale is described clearly and the 
manuscript reports the important observation on the inhibition of fatty 
acid oxidation and underlying enzymes in female rat liver; however, a 
number of points need to be clarified. 
In addition, the discussion is hard to follow. Therefore, a revision of 
manuscript as well as an addition of a diagram that summarizes the 
interaction between transcription factors leading to the activation or 
inhibition of PPARα and fatty acid oxidation would be very helpful.  
According to the referee’s suggestion, we have revised the discussion and 
added a figure (new Figure 7) to make it easier to follow. 
Specific comments: 
Introduction: 
-The introduction is very short and in my opinion it is not complete. For 
instance, it doesn't give the logics behind measuring PPARα expression 
and activity. The role of PPARα in the fatty acid oxidation should be 
stated. This justifies why the authors measuring liver transcription 
factors and enzymes controlling PPARα.  In addition, the authors should 
introduce the PP2A and its possible role in the in PPARα activity in 
Introduction. This justifies the use of okadaic acid and the Enzyme 
(PP2A) activity assays in Method section (2.5). 
The role of PPARα on fatty acid oxidation, as well as the possible role 
of PP2A in the inhibition of the PPARα system has been clearly stated in 
the introduction section in the new version of the manuscript (pg 4 ln 
21-23 and pg 5 ln 1-3).  
-Please rephrase the following statement:  
Page 4: "Reported reasons are high energy intake, lack of adequate energy 
compensation and the special metabolism of fructose [1,5]." 
The sentence has been rephrased as: “High energy intake, lack of adequate 
energy compensation and the special metabolism of fructose have been 
reported as reasons to explain this association [1,5].” 
-Page 4: "As we wanted to understand the mechanism of fructose effects, 
we studied the effect of fructose. 
You may rephrase it as "The aim of our study was to investigate the 
effect of fructose.. 
We have re-written the sentence as the referee suggests 
Methods: 
-It requires the justification for selection of use of 7 or 14 days and 
10% fructose for 7-14 days or 25 mM for 24 h in vitro.  How comparable or 
relevant these concentrations of fructose are to in vivo ingestion by 
human? Is it considered the medium range of ingestion or high?  
Diets that incorporate 10 % weight/volume fructose concentrations in 
drinking water mimic the human pattern of fructose consumption, with 
daily fructose intake equivalent to that found in the upper quartile of 
fructose consumption in human populations. We have used this model of 
fructose administration during 14 days in several previous studies, e.g. 
Roglans N et al., Hepatology 2007, 45:778. In the present article we 
wanted also to study fructose effects at an earlier time point (7 days) 
and also, to avoid fluctuations in the amount of sugar ingested in the in 
vivo studies, to assess the effects of fructose on liver in vitro. 
Concentrations of fructose in the portal circulation can easily reach 5–
10 mM (Du L, Heaney AP. Mol Endocrinol. 2012, 26:1773), but as for in 
vitro studies incubation times cannot be as long as in vivo exposure 
times, we decided to use higher fructose concentrations (25 mM), similar 
to previous studies of our group (Vilà et al., Hepatology 2008, 48:1506; 
Rodriguez-Calvo R et al., Hepatology 2009, 49:106).  
 
-Page 6: In some experiments, 100 μM of Wy-14643 and 20 nM of Okadaic 
acid were added 3 hours and 30 minutes, respectively, before fructose. 
100 nM of SRT1720 was added to the medium 12 hours after fructose 
supplementation. 
Please state the action of these drugs when stated the first time in the 
manuscript. For instance, Wy-14643 (a PPARα ligand), Okadaic acid (an 
inhibitor of PP2A), SRT1720 (a selective activator of SIRT1), Okadaic 
acid (an inhibitor of PP2A) 
According to the referee’s suggestion, we have defined the action of the 
drugs when first cited in the Methods section.  
-Page 7, section 2.5: The concentration and the duration of treatment 
with TSA are missing. 
TSA was added at a concentration of 1 µM for 12 h. This has been added in 
the new version of the manuscript (pg 7, section 2.5). 
-Page 7, section 2.6: Why were different internal controls used for 7 and 
14 days fructose supplemented rats? APRT was used for 7 days and 18s for 
14 days group of rats. 
The referee may be mistaken, as in fact we used APRT for 14 days and 18 s 
for 7 days. In our previous studies in rats treated with fructose for 14 
days we always used APRT as an internal control. However, when we started 
experiments using shorter treatment periods, we observed that the 
expression of APRT changed in samples from fructose-fed rats compared 
with controls. Therefore, we decided to use 18s as an internal control 
for these samples. 
-Page 8, Section 2.7: It requires more details on the Western blot 
analysis. 
In the new version of the manuscript we have provided more details, such 
as blocking conditions, dilutions of each primary antibody and conditions 
of incubation with secondary antibodies (pg 8 ln 22- pg 9 ln 11). 
Results: 
-According to the table 1, it seems there is a tendency for increase of 
leptin in both 7 and 14 days fructose supplementation to rats. Regardless 
the fatty acid oxidation is inhibited. This point should be discussed in 
Discussion. Have the authors also measured the level of adiponectin?  
The differences in plasma leptin levels between control and fructose-
treated rats are not statistically significant. Consequently, we consider 
that there is no need to speculate on this issue. On the other hand, we 
measured plasma adiponectin levels. These results have now been included 
in Table 1 and in page 11 in the new version of the manuscript. There is 
a significant increase in plasma adiponectin levels only in rats 
supplemented with fructose for 14 days. This increase was also detected 
in previous studies in male rats supplemented with either 10% glucose or 
10% fructose (Roglans N et al., Hepatology 2007, 45:778), suggesting that 
this is not a specific effect of fructose. We do not believe that this 
data has enough relevance to be discussed in the article. 
-Page 10, Section 3.1: How was the degree of steatosis measured in the 
fructose ingested groups, and how compared between two groups of 7- and 
14-days fructose supplemetation? The authors did not give any values but 
stated that liver steatosis was confirmed by histological analysis.  
We quantified the amount of triglycerides in hepatic samples from 
fructose-supplemented and control rats. As shown in Table 1, the hepatic 
triglyceride content was not significantly increased after 7 days of 
fructose supplementation, but there was an increase of 1.9-fold (from 4.1 
± 2.3 to 7.7 ± 2.4 mg/g liver, p<0.05) after 14 days of treatment. 
Steatosis was confirmed qualitatively by histological analysis in liver 
sections stained with Oil Red O (Figure 1 C). 
-Page 11, section 3.3: It is still unclear why the PPARα expression was 
increased in 7 days fructose supplementation to rats.  This should be 
discussed in Discussion. 
It is interesting to discuss why fatty acid oxidation is repressed at 7 
days despite higher PPARα activity. It is probably due to higher ACC 
expression leading to malonyl-CoA production, which inhibits L-CPT1 and 
therefore reduces beta oxidation activity. We have included this in the 
Discussion section in the new version of the manuscript (page 16, ln 18-
20). We are not certain about the mechanisms by which the expression and 
activity of PPARα at 7 days is increased. It is possible that in this 
situation there is an increase in endogenous PPARα ligands, or changes in 
the expression of co-activators and co-repressors leading to an increase 
of PPARα expression and its target genes.  
-Page 11, Section 3.3:  The authors mentioned about the possible 
mechanisms which are responsible for inhibition of fatty acid β-
oxidation, despite opposite changes in PPARα. "This inhibition of fatty 
acid β-oxidation, despite opposite changes in PPARα, could be attributed 
to two mechanisms: 1. Livers from 7- and 14-day fructose supplemented 
rats showed increased expression of total and phosphorylated ACC (Table 
2), implying increased production of malonyl-CoA, a known allosteric 
inhibitor of L-CPT-I, whose activity controls the whole fatty acid β-
oxidation system [24]; 2. ChREBP activity controls the expression of 
RGS16, a physiological inhibitor of the fatty β- oxidation system [25]." 
First of all, the above statements should be moved to Discussion, and if 
I understand it correctly, in both 7- and 14-days fructose 
supplementation, the RGS16 was enhanced (Fig 2C). If the ChREBP activity 
controls the RGS16 (inhibitor of FA oxidation), please then clarify that 
as how the ChREBP was enhanced only in 14-days supplementation?  
In order to follow the rationale behind the shown experiments, we 
consider that this piece of text is correctly placed in this section. The 
referee is right; the mRNA levels of RGS16 are equally increased at both 
time-points. To be sure of the physiological meaning of this induction, 
we measured the protein expression of RGS16 in hepatic samples from 
fructose-supplemented and control rats. The protein levels were not 
modified at any of the treatment times, ruling out the involvement of 
RGS16 in the inhibition of hepatic fatty acid oxidation: 
7days: 
Control Fructose 
1.00 ± 0.14 1.04 ± 0.36 
 
 
 
14 days: 
 
Control Fructose 
1.00 ± 0.17 1.09 ± 1.12 
 
 
 
This information has been added in the new version of the manuscript (new 
Figure 2D) and in the discussion (pg 18, ln 9-12).  
Here, the authors explaining the inhibition of fatty acid β-oxidation, 
despite opposite changes in PPARα through 1) enhanced production of 
malonyl-CoA through ACC phosphorylation and 2) Deacetylation and 
activation of PGC-1α (a cofactor of PPARα, necessary for the 
transcriptional control of genes related to fatty acid oxidation.  
We know Malonyl CoA is synthesized in the liver by ACC, which in turn is 
phosphorylated and inhibited by AMPK. On the other hand, AMPK increases 
FA oxidation directly by PPARα activation.   It would be interesting to 
measure the AMPK expression or activity in both 7 and 14-day fructose 
supplementation and to see whether its level is reduced in these groups. 
I am not suggesting additional experiments, but if the AMPK level was 
measured already, it would be nice to include it. 
According to the referee’s suggestion, we measured the expression of 
total and phosphorylated AMPK, and we did not observe significant 
differences between control and fructose-supplemented animals. These 
results have been included in the new version of the manuscript (Table 
3). 
 7days 14 days 
 Control Fructose Control Fructose 
p-AMPK 1.00 ± 0.32 1.06 ± 0.20 1.00 ± 0.24 0.91 ± 0.14 
Total AMPK 1.00 ± 0.34 0.98 ± 0.17 1.00 ± 0.28 1.28 ± 0.20 
 The lack of increase in phospho-AMPK suggests that its kinase activity is 
not enhanced. Consequently, the ratio between phosphorylated and total 
ACC is not increased. Thus, the increase in ACC expression as a 
consequence of the activation of lipogenesis should lead to an increase 
in malonyl-CoA production.  
A decrease in SIRT1 expression and activity (based on NAMPT) (Figs 6A-B) 
and consistently inactivity of PGC-1 (Fig 6D) could be responsible for 
the reduced PPARα and reduced FA oxidation in 14-day fructose 
supplementation group. However, it is still unclear how we get to an 
increased PPARα in 7-day fructose supplementation. Obviously we see no 
changes in SIRT1 expression and in NAMPT in this group.  
We agree with the referee, the increase in the expression and activity of 
PPARα at 7 days is not related to changes in SIRT1 or NAMPT expression. 
Our hypothesis is that PPARα increase at 7 days could be a compensatory 
mechanism, an attempt to enhance fatty acid oxidation in the initial 
phases of fructose consumption, maybe related to an increase in 
endogenous PPARα ligands, or to changes in the expression of co-
activators and co-repressors.  
-The authors also mentioned that "The liver fatty acid β-oxidation system 
was probably repressed by products of the metabolism of fructose at the 
time of death, independently of the actual expression and transcriptional 
activity of PPARα."  
This hypothesis need to be more clarified based on their data and 
observation.  
As this sentence was confusing, we have deleted it in the new version of 
the manuscript.  
-Figure 2C: How do you explain so much variability in mRNA bands of RGS16 
of controls (n= 3)?   
There was a mistake in the legend for Figure 2. Instead of “Each bar 
represents the mean±sd of three different samples” it should read “Each 
bar represents the mean±sd of values obtained from n=4 and n=5 animals 
(for control and fructose groups, respectively).” The autoradiography 
above the figure shows the bands corresponding to Rsg16 mRNA and that of 
the aprt gene, used as an internal control in the PCR reaction to 
normalize the results, from liver samples of 3 animals from each 
treatment group. We have corrected the mistake in the figure legend. We 
cannot explain the variability, but we are confident in our results, 
because they come from 4-5 different animals per group of treatment. 
Moreover, when we performed statistical analysis, we found that the 
increase was statistically significant, despite the variability. 
-Page 13, PGS16 needs to be replaced by RGS16. RGS16 stands for 
"Regulator of G protein signaling".This should be added to the 
Manuscript.  
The complete name of the protein has been added in the new version of the 
manuscript. 
-Page 14: The following statement should be moved to Discussion.  
"Thus, the effect of fructose on the expression of these genes was 
independent of PP2A activity, corroborating previous research by Dentin 
et al. [28]." 
The statement has been rephrased and moved  
-Page 14, section 3.6:  In Table 3, the authors showed that the 
expression of Foxa2, a transcription factor regulating fatty acid 
oxidation, was reduced only after 14-day fructose supplementation. 
However β oxidation of fatty acid was reduced after both 7 and 14-day 
fructose supplementation. This requires further clarification. 
The reduction of Foxa2 expression after 14 days of fructose treatment, 
although significant is just of 13%. This suggests that its biological 
significance is not relevant, and does not deserve further consideration.  
-Page 14, Section 3.6: The authors stated "fructose was also able to 
efficiently block the increase in PPARα expression induced by incubating 
FaO cells with SRT1720, a potent and selective activator of SIRT1 [31] 
(Figure 6). " 
Figure 6 must be replaced by Figure 6C.  
The replacement has been done as indicated by the referee. 
-There is no any text in this section referring to Figure 6E. 
It is an error, as Figure 6E corresponds to the levels of acetylated 
ChREBP protein in liver samples from control and 14-day fructose-
supplemented rats, but in the text it was cited as 4E. This error has 
been corrected in the new version of the manuscript (pg 19, ln 1). 
Discussion 
-In general, the Discussion is difficult to follow. It needs to be 
revised in a way that can be more interactive and clear. Perhaps an 
addition of a diagram would be helpful.  
According to the referee’s suggestion, we have revised the discussion and 
added a figure (new Figure 7) to make it easier to follow. 
-In the first paragraph, the authors stated that "Here, we demonstrate 
that fructose inhibits liver fatty acid β-oxidation by reducing PPARα 
expression and activity, mainly by decreasing the expression and activity 
of SIRT1." 
Please be more précised as this was shown only after 14-day fructose 
supplementation.   
We have modified the sentence, and added some discussion on fructose 
effects at 7 days (pg 16, ln 18-20) of the new version of the 
manuscript).  
-Page 16: Please rephrase following statement: "Thus, we were 
disappointed that fructose incubation of FaO cells, despite reducing 
PPARα expression, did not reduce SIRT1 and NAMPT. 
We have rephrased the sentence as: “However, fructose incubation of FaO 
cells, despite reducing PPARα expression, did not reduce SIRT1 and NAMPT” 
-Page 16: It is not clear to me as how a short incubation period of FaO 
cell with fructose is not sufficient to repress the SIRT1 expression, but 
reduces its deacetylase activity strongly enough to reduce the expression 
of PPARα. In addition, a question arises as how long incubation of FaO 
cells with fructose could be sufficient to repress the SIRT1 expression? 
Our data shows that fructose at high concentrations directly or 
indirectly inhibits SIRT1 activity without modifying SIRT1 expression. We 
don’t know how much time would be necessary to modify SIRT1 expression, 
but we could not extend incubation times for longer than 48 h in FaO 
cells. 
-Page 17: The author stated that "we also found an increased amount of 
acetylated-ChREBP protein in livers of 14-day fructose-supplemented rats 
(Figure 4E)".  
I assume the right figure for the above statement is 6E and not 4E. 4E 
should be replaced by 6E. 
Yes, the referee is right; we have replaced 4E by 6E in the new version 
of the manuscript. 
-Page 17: The authors concluded that “In conclusion, fructose depresses 
PPARα expression and activity, and thus fatty acid β-oxidation, in rat 
liver cells and human hepatocytes by a mechanism involving a reduction of 
SIRT1 expression and activity”  
The decreased of PPARα expression and activity was observed after 14 days 
fructose supplementation and a reduction of SIRT1 was not observed in rat 
liver cells. Please revise the above statement to reflect the 
observations accordingly. 
According to the referee’s suggestion, we have revised this final 
statement and reformulated it to reflect more precisely the main 
conclusions of our study: “In conclusion, fructose depresses PPARα 
expression and activity, in hepatic tissue from 14-days fructose-
supplemented rats and in rat and human liver cells, by a mechanism that 
could involve a concerted increase in ChREBP and a reduction of SIRT1 
expression and activity." This has been included in the new version of 
the manuscript (Discussion, pg 19, last paragraph). 
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Dr. Rudolf Zechner 
 
Executive Editor 
BBA – Molecular and Cell Biology of Lipids 
   
 Barcelona, December 13, 2013 
 Dear Dr. Zechner,  
We are re-submitting to the Biochimica and Biophysica Acta-Molecular and Cell 
Biology of Lipids journal  the manuscript entitled “LIQUID FRUCTOSE DOWNREGU-
LATES SIRT1 EXPRESSION AND ACTIVITY AND IMPAIRS THE OXIDATION OF 
FATTY ACIDS IN RAT AND HUMAN LIVER CELLS”, authored by Alba Rebollo, Núria 
Roglans, Miguel Baena, Rosa M Sánchez, Manuel Merlos, Marta Alegret and Juan C 
Laguna.  As you will see in the new version of the manuscript, we have followed the 
majority of suggestions proposed by the referees, including new data and a new figure 
(Figure 7). We include a letter answering all the referees’ queries, properly discussing 
our position when the referee’s query is refuted.  
We appreciate very much the opportunity of resubmission; we are convinced, and we 
deeply expect that you too, that the new version of the manuscript is much improved 
and will merit your approval. 
 
Yours sincerely, 
Dr. Juan C. Laguna 
Cover Letter
Reviewer #1:  
Major points: 
1. In order for the reader to comprehend the nutritional setting in which the changes are 
being observed, far more detail needs to be included to support/strengthen table 1.  Details on 
the nutritional content of the diet must be included (% calories from fat etc..). In the same 
sense, it would be useful to see the data presented as total calories consumed from diet vs 
fructose in drinking water.  
In this study the rats received a regular diet (Teklad Global 2018 Rodent Diet, fromHarlan 
Teklad), that provided 18% calories from fat, 24% from protein and 58% from carbohydrate. 
This information has been included in the new version of the manuscript (Materials and 
Methods section, pg 5, ln 22-23). 
Regarding the calories consumed from diet or from fructose, we calculated the data from the 
area under the curve of food or drink consumption in g or ml/days/cage (containing two rats). 
Our results are the following: 
 7days 14 days 
 Control Fructose Control Fructose 
Kcal from food 726.4 566.4 1609.6 1254.4 
Kcal from drink 0 338 0 798 
Total kcal 726.4 904.4 1609.6 2052.4 
 
As we already stated in our first version of the manuscript, “rats increased their calorie intake 
in a similar way at 7 (x1.24-fold) and 14 days (x1.27-fold), mainly due to an increase in fructose 
calories (x1.37 and x1.39-fold at 7 and 14 days, respectively), which was not compensated by a 
reduction in the ingestion of solid food”. Perhaps it was not clear enough, so we have 
rephrased the sentence (pg 11, ln  8-13): “rats increased their calorie intake in a similar way, 
from 726.4 to 904.4 kcal/7days/2 rats (increase of 1.24-fold) and from 1609.6 to 2052.4  
kcal/14days/2 rats (x1.27-fold), at 7 and 14 days, respectively. The increase was mainly due to 
calories obtained from fructose, which represented a 37 and 39% of the total calories 
consumed at 7 and 14 days, respectively. This increase was not compensated by a sufficient 
reduction in the ingestion of solid food” 
2. The authors state that body weight changes were not observed, but the values should 
be included for the readers' benefit, and it would also be beneficial to know roughly what was 
happening in other key metabolic tissues, such as adipose tissue. For instance leptin levels 
increase significantly at 14 weeks, suggestive of an expansion of adipose tissue lipid content. 
One might postulate that in the face of impaired lipid oxidation, the liver is exporting more 
triglyceride in VLDL particles which are being taken up by the white fat. Basic histological 
examination of WAT and tissue weights would be good and examination measurement of key 
lipid handling genes even better. Likewise, analysis of lipid synthetic genes or genes regulating 
triglyceride release (MTP) in liver would be illuminating in this sense. The increased serum TG 
have to be coming from somewhere - and the data indicate that it is not from the diet. 
Response to Reviewers
As the referee suggest, we have included body weight and white adipose tissue weight data in 
Table 1 of the new version of the manuscript. As can be seen in this table, there is no 
significant difference in total body weight (either expressed as area under the curve in g/7 or 
14 days/rat or as body weight at the end of treatment) between control and fructose groups.  
Regarding adipose tissue weight, we neither observed statistically significant changes. On the 
other hand, plasma leptin levels are not significantly increased at 14 days 
Further, we already measured the expression of the genes involved in lipid synthesis, 
specifically liver-pyruvate kinase (L-PK), fatty acid synthase (FAS), stearoyl-CoA desaturase 
(SCD1), glycerol phosphate acyltransferase 1 (GPAT1) and acetyl-CoA carboxylase (ACC), and 
we found that fructose similarly induced their expression after 7- and 14-day supplementation 
(data in Table 2). Thus, serum and hepatic triglycerides come from the combined increase in 
lipid synthesis and reduction of fatty acid oxidation.  
Regarding additional experiments suggested by the referee, we did not perform basic 
histological examination of WAT at the moment of sacrifice. Nevertheless, we could determine 
the mRNA levels of MTP in hepatic samples from treated animals. Our results were: 
 7days 14 days 
 Control Fructose Control Fructose 
MTP 1 ± 0.14 1.21 ± 0.40 1 ±0.19 1.33 ± 0.33 
 
The lack of increase of MTP expression is not surprising, as MTP expression is regulated by 
reduced lipid availability, but an increase in the amount of lipids would not necessarily induce 
MTP expression. It would have been better to determine MTP activity, but this has to be 
performed in freshly obtained hepatic samples. 
3. Long chain fatty acid beta-oxidation is clearly impaired by fructose treatment, but is 
there any compensation via increased oxidation of short chain fatty acids? Are genes 
regulating fatty acid elongation down-regulated for instance? 
In our study we fed rats with a regular chow diet that did not provide short chain fatty acids 
(SCFA) but long chain fatty acids (LCFA: palmitic, stearic, oleic, linoleic and linolenic acids). 
SCFA could also be formed from colonic fermentation of dietary fiber, but the regular chow 
that we used in our study has a low amount of crude fiber (3.5%), and moreover, its 
consumption was reduced in fructose-supplemented animals. Thus, the bulk of fatty acids 
reaching the hepatic cells of the rats in our study are LCFA. In this case, SCFA could only derive 
from the β-oxidation of these LCFA, but as this is reduced in fructose-fed rats, the amount of 
SCFA formed should also be reduced. Therefore, if a compensatory response of increased SCFA 
oxidation existed, it would not result in a meaningful metabolic effect. 
Regarding fatty acid elongation, there are some reports showing that the expression of hepatic 
elongases (Elovl) might be controlled by several hormones and transcription factors, including 
PPARα, SREBP-1 and ChREBP (Wang et al., J Lipid Res. 2005, 46:706; Wang et al., J Lipid Res. 
2006, 47: 2028). It has been shown that carbohydrates induce hepatic Elovl-6 along with L-PK 
and FAS through ChREBP (Wang et al., J Lipid Res. 2006, 47:2028). Thus, as the referee 
suggested, we decided to determine the expression of hepatic Elovl-6 in hepatic samples from 
our control and fructose-supplemented rats. According to the general induction of genes 
involved in lipid synthesis, we also found a significant increase in Elovl6 expression at both 7 
and 14 days. These results have been included in the text (pg 12, ln 4 and in Table 2).  
4. What effects are there on other key lipid-burning tissues? For instance what happens to 
beta-oxidative genes and UCP1 in the brown adipose tissue? This data would enable the 
specificity and relative contribution of the effects of fructose on hepatic lipid metabolism 
Unfortunately, we did not obtain brown adipose tissue (BAT) from the rats of our study. UCP-1 
is a hallmark of BAT and under basal conditions it is not expressed in white adipose tissue 
(WAT). A recent report (Li et al, Gastroenterology, Epub ahead of print 2013 Oct 31, doi: 
10.1053/j.gastro.2013.10.059) showed that increased SIRT-1 activity increases the levels of the  
hepatocyte-derived hormone fibroblast growth factor 21 (FGF21), and this enhanced energy 
expenditure through white fat “browning” (with increased expression in WAT of typical BAT 
genes such as UCP-1). However, in our study we detected a decrease, not an increase in SIRT-1 
expression and activity. Moreover, we did not observe changes in the mRNA expression of 
hepatic FGF21 after 14 days of fructose supplementation (data not shown in the paper). Thus, 
hepatic FGF21 mRNA levels, expressed in arbitrary units were 1.00 ± 0.44 (control rats) and 
0.93 ± 0.27 (fructose-supplemented rats). These results suggest that UCP-1 would not be 
expressed in WAT from fructose-supplemented animals. 
Minor points: 
1. The concept that mitochondrial long-chain fatty acid oxidation is impaired by fructose is not 
novel. In fact a paper from 1976 already demonstrates this effect and should at least be cited. 
(Prager GN, Ontko JA. Direct effects of fructose metabolism on fatty acid oxidation in a 
recombined rat liver mitochondria-high speed supernatant system. Biochim Biophys Acta. 1976 
Mar 26;424(3):386-95.) 
According to the referee’s suggestion we have cited this reference in the novel version of the 
manuscript (pg 4 ln 15-16) 
2. Table one title should read "liver triglycerides". 
The spelling error has been corrected in the new version of the manuscript. 
3. Figure 6E does not appear to be discussed in the text? 
This was also an error, as Figure 6E corresponds to the levels of acetylated ChREBP protein in 
liver samples from control and 14-day fructose-supplemented rats, but in the text it was cited 
as 4E. This error has been corrected in the new version of the manuscript (pg 19, ln 1). 
Reviewer #2 
General comments: 
This is a short manuscript. The rationale is described clearly and the manuscript reports the 
important observation on the inhibition of fatty acid oxidation and underlying enzymes in 
female rat liver; however, a number of points need to be clarified. 
In addition, the discussion is hard to follow. Therefore, a revision of manuscript as well as an 
addition of a diagram that summarizes the interaction between transcription factors leading to 
the activation or inhibition of PPAR<alpha> and fatty acid oxidation would be very helpful.  
According to the referee’s suggestion, we have revised the discussion and added a figure (new 
Figure 7) to make it easier to follow. 
Specific comments: 
Introduction: 
-The introduction is very short and in my opinion it is not complete. For instance, it doesn't give 
the logics behind measuring PPAR<alpha> expression and activity. The role of PPAR<alpha> in 
the fatty acid oxidation should be stated. This justifies why the authors measuring liver 
transcription factors and enzymes controlling PPAR<alpha>.  In addition, the authors should 
introduce the PP2A and its possible role in the in PPAR<alpha> activity in Introduction. This 
justifies the use of okadaic acid and the Enzyme (PP2A) activity assays in Method section (2.5). 
The role of PPARα on fatty acid oxidation, as well as the possible role of PP2A in the inhibition 
of the PPARα system has been clearly stated in the introduction section in the new version of 
the manuscript (pg 4 ln 21-23 and pg 5 ln 1-3).  
-Please rephrase the following statement:  
Page 4: "Reported reasons are high energy intake, lack of adequate energy compensation and 
the special metabolism of fructose [1,5]." 
The sentence has been rephrased as: “High energy intake, lack of adequate energy 
compensation and the special metabolism of fructose have been reported as reasons to 
explain this association [1,5].” 
-Page 4: "As we wanted to understand the mechanism of fructose effects, we studied the effect 
of fructose. 
You may rephrase it as "The aim of our study was to investigate the effect of fructose.. 
We have re-written the sentence as the referee suggests 
Methods: 
-It requires the justification for selection of use of 7 or 14 days and 10% fructose for 7-14 days 
or 25 mM for 24 h in vitro.  How comparable or relevant these concentrations of fructose are to 
in vivo ingestion by human? Is it considered the medium range of ingestion or high?  
Diets that incorporate 10 % weight/volume fructose concentrations in drinking water mimic 
the human pattern of fructose consumption, with daily fructose intake equivalent to that 
found in the upper quartile of fructose consumption in human populations. We have used this 
model of fructose administration during 14 days in several previous studies, e.g. Roglans N et 
al., Hepatology 2007, 45:778. In the present article we wanted also to study fructose effects at 
an earlier time point (7 days) and also, to avoid fluctuations in the amount of sugar ingested in 
the in vivo studies, to assess the effects of fructose on liver in vitro. Concentrations of fructose 
in the portal circulation can easily reach 5–10 mM (Du L, Heaney AP. Mol Endocrinol. 2012, 
26:1773), but as for in vitro studies incubation times cannot be as long as in vivo exposure 
times, we decided to use higher fructose concentrations (25 mM), similar to previous studies 
of our group (Vilà et al., Hepatology 2008, 48:1506; Rodriguez-Calvo R et al., Hepatology 2009, 
49:106).  
 
-Page 6: In some experiments, 100 <mu>M of Wy-14643 and 20 nM of Okadaic acid were 
added 3 hours and 30 minutes, respectively, before fructose. 100 nM of SRT1720 was added to 
the medium 12 hours after fructose supplementation. 
Please state the action of these drugs when stated the first time in the manuscript. For 
instance, Wy-14643 (a PPAR<alpha> ligand), Okadaic acid (an inhibitor of PP2A), SRT1720 (a 
selective activator of SIRT1), Okadaic acid (an inhibitor of PP2A) 
According to the referee’s suggestion, we have defined the action of the drugs when first cited 
in the Methods section.  
-Page 7, section 2.5: The concentration and the duration of treatment with TSA are missing. 
TSA was added at a concentration of 1 µM for 12 h. This has been added in the new version of 
the manuscript (pg 7, section 2.5). 
-Page 7, section 2.6: Why were different internal controls used for 7 and 14 days fructose 
supplemented rats? APRT was used for 7 days and 18s for 14 days group of rats. 
The referee may be mistaken, as in fact we used APRT for 14 days and 18 s for 7 days. In our 
previous studies in rats treated with fructose for 14 days we always used APRT as an internal 
control. However, when we started experiments using shorter treatment periods, we observed 
that the expression of APRT changed in samples from fructose-fed rats compared with 
controls. Therefore, we decided to use 18s as an internal control for these samples. 
-Page 8, Section 2.7: It requires more details on the Western blot analysis. 
In the new version of the manuscript we have provided more details, such as blocking 
conditions, dilutions of each primary antibody and conditions of incubation with secondary 
antibodies (pg 8 ln 22- pg 9 ln 11). 
Results: 
-According to the table 1, it seems there is a tendency for increase of leptin in both 7 and 14 
days fructose supplementation to rats. Regardless the fatty acid oxidation is inhibited. This 
point should be discussed in Discussion. Have the authors also measured the level of 
adiponectin?  
The differences in plasma leptin levels between control and fructose-treated rats are not 
statistically significant. Consequently, we consider that there is no need to speculate on this 
issue. On the other hand, we measured plasma adiponectin levels. These results have now 
been included in Table 1 and in page 11 in the new version of the manuscript. There is a 
significant increase in plasma adiponectin levels only in rats supplemented with fructose for 14 
days. This increase was also detected in previous studies in male rats supplemented with 
either 10% glucose or 10% fructose (Roglans N et al., Hepatology 2007, 45:778), suggesting 
that this is not a specific effect of fructose. We do not believe that this data has enough 
relevance to be discussed in the article. 
-Page 10, Section 3.1: How was the degree of steatosis measured in the fructose ingested 
groups, and how compared between two groups of 7- and 14-days fructose supplemetation? 
The authors did not give any values but stated that liver steatosis was confirmed by histological 
analysis.  
We quantified the amount of triglycerides in hepatic samples from fructose-supplemented and 
control rats. As shown in Table 1, the hepatic triglyceride content was not significantly 
increased after 7 days of fructose supplementation, but there was an increase of 1.9-fold (from 
4.1 ± 2.3 to 7.7 ± 2.4 mg/g liver, p<0.05) after 14 days of treatment. Steatosis was confirmed 
qualitatively by histological analysis in liver sections stained with Oil Red O (Figure 1 C). 
-Page 11, section 3.3: It is still unclear why the PPAR<alpha> expression was increased in 7 days 
fructose supplementation to rats.  This should be discussed in Discussion. 
It is interesting to discuss why fatty acid oxidation is repressed at 7 days despite higher PPARα 
activity. It is probably due to higher ACC expression leading to malonyl-CoA production, which 
inhibits L-CPT1 and therefore reduces beta oxidation activity. We have included this in the 
Discussion section in the new version of the manuscript (page 16, ln 18-20). We are not certain 
about the mechanisms by which the expression and activity of PPARα at 7 days is increased. It 
is possible that in this situation there is an increase in endogenous PPARα ligands, or changes 
in the expression of co-activators and co-repressors leading to an increase of PPARα 
expression and its target genes.  
-Page 11, Section 3.3:  The authors mentioned about the possible mechanisms which are 
responsible for inhibition of fatty acid <beta>-oxidation, despite opposite changes in 
PPAR<alpha>. "This inhibition of fatty acid <beta>-oxidation, despite opposite changes in 
PPAR<alpha>, could be attributed to two mechanisms: 1. Livers from 7- and 14-day fructose 
supplemented rats showed increased expression of total and phosphorylated ACC (Table 2), 
implying increased production of malonyl-CoA, a known allosteric inhibitor of L-CPT-I, whose 
activity controls the whole fatty acid <beta>-oxidation system [24]; 2. ChREBP activity controls 
the expression of RGS16, a physiological inhibitor of the fatty <beta>- oxidation system [25]." 
First of all, the above statements should be moved to Discussion, and if I understand it 
correctly, in both 7- and 14-days fructose supplementation, the RGS16 was enhanced (Fig 2C). 
If the ChREBP activity controls the RGS16 (inhibitor of FA oxidation), please then clarify that as 
how the ChREBP was enhanced only in 14-days supplementation?  
In order to follow the rationale behind the shown experiments, we consider that this piece of 
text is correctly placed in this section. The referee is right; the mRNA levels of RGS16 are 
equally increased at both time-points. To be sure of the physiological meaning of this 
induction, we measured the protein expression of RGS16 in hepatic samples from fructose-
supplemented and control rats. The protein levels were not modified at any of the treatment 
times, ruling out the involvement of RGS16 in the inhibition of hepatic fatty acid oxidation: 
7days: 
Control Fructose 
1.00 ± 0.14 1.04 ± 0.36 
 
 
 
14 days: 
 
Control Fructose 
1.00 ± 0.17 1.09 ± 1.12 
 
 
 
This information has been added in the new version of the manuscript (new Figure 2D) and in 
the discussion (pg 18, ln 9-12).  
Here, the authors explaining the inhibition of fatty acid <beta>-oxidation, despite opposite 
changes in PPAR<alpha> through 1) enhanced production of malonyl-CoA through ACC 
phosphorylation and 2) Deacetylation and activation of PGC-1<alpha> (a cofactor of 
PPAR<alpha>, necessary for the transcriptional control of genes related to fatty acid oxidation.  
We know Malonyl CoA is synthesized in the liver by ACC, which in turn is phosphorylated and 
inhibited by AMPK. On the other hand, AMPK increases FA oxidation directly by PPAR<alpha> 
activation.   It would be interesting to measure the AMPK expression or activity in both 7 and 
14-day fructose supplementation and to see whether its level is reduced in these groups. I am 
not suggesting additional experiments, but if the AMPK level was measured already, it would 
be nice to include it. 
According to the referee’s suggestion, we measured the expression of total and 
phosphorylated AMPK, and we did not observe significant differences between control and 
fructose-supplemented animals. These results have been included in the new version of the 
manuscript (Table 3). 
 7days 14 days 
 Control Fructose Control Fructose 
p-AMPK 1.00 ± 0.32 1.06 ± 0.20 1.00 ± 0.24 0.91 ± 0.14 
Total AMPK 1.00 ± 0.34 0.98 ± 0.17 1.00 ± 0.28 1.28 ± 0.20 
 
The lack of increase in phospho-AMPK suggests that its kinase activity is not enhanced. 
Consequently, the ratio between phosphorylated and total ACC is not increased. Thus, the 
increase in ACC expression as a consequence of the activation of lipogenesis should lead to an 
increase in malonyl-CoA production.  
A decrease in SIRT1 expression and activity (based on NAMPT) (Figs 6A-B) and consistently 
inactivity of PGC-1 (Fig 6D) could be responsible for the reduced PPAR<alpha> and reduced FA 
oxidation in 14-day fructose supplementation group. However, it is still unclear how we get to 
an increased PPAR<alpha> in 7-day fructose supplementation. Obviously we see no changes in 
SIRT1 expression and in NAMPT in this group.  
We agree with the referee, the increase in the expression and activity of PPARα at 7 days is not 
related to changes in SIRT1 or NAMPT expression. Our hypothesis is that PPARα increase at 7 
days could be a compensatory mechanism, an attempt to enhance fatty acid oxidation in the 
initial phases of fructose consumption, maybe related to an increase in endogenous PPARα 
ligands, or to changes in the expression of co-activators and co-repressors.  
-The authors also mentioned that "The liver fatty acid <beta>-oxidation system was probably 
repressed by products of the metabolism of fructose at the time of death, independently of the 
actual expression and transcriptional activity of PPAR<alpha>."  
This hypothesis need to be more clarified based on their data and observation.  
As this sentence was confusing, we have deleted it in the new version of the manuscript.  
-Figure 2C: How do you explain so much variability in mRNA bands of RGS16 of controls (n= 3)?   
There was a mistake in the legend for Figure 2. Instead of “Each bar represents the mean±sd of 
three different samples” it should read “Each bar represents the mean±sd of values obtained 
from n=4 and n=5 animals (for control and fructose groups, respectively).” The 
autoradiography above the figure shows the bands corresponding to Rsg16 mRNA and that of 
the aprt gene, used as an internal control in the PCR reaction to normalize the results, from 
liver samples of 3 animals from each treatment group. We have corrected the mistake in the 
figure legend. We cannot explain the variability, but we are confident in our results, because 
they come from 4-5 different animals per group of treatment. Moreover, when we performed 
statistical analysis, we found that the increase was statistically significant, despite the 
variability. 
-Page 13, PGS16 needs to be replaced by RGS16. RGS16 stands for "Regulator of G protein 
signaling".This should be added to the Manuscript.  
The complete name of the protein has been added in the new version of the manuscript. 
-Page 14: The following statement should be moved to Discussion.  
"Thus, the effect of fructose on the expression of these genes was independent of PP2A activity, 
corroborating previous research by Dentin et al. [28]." 
The statement has been rephrased and moved  
-Page 14, section 3.6:  In Table 3, the authors showed that the expression of Foxa2, a 
transcription factor regulating fatty acid oxidation, was reduced only after 14-day fructose 
supplementation. However <beta> oxidation of fatty acid was reduced after both 7 and 14-day 
fructose supplementation. This requires further clarification. 
The reduction of Foxa2 expression after 14 days of fructose treatment, although significant is 
just of 13%. This suggests that its biological significance is not relevant, and does not deserve 
further consideration.  
-Page 14, Section 3.6: The authors stated "fructose was also able to efficiently block the 
increase in PPAR<alpha> expression induced by incubating FaO cells with SRT1720, a potent 
and selective activator of SIRT1 [31] (Figure 6). " 
Figure 6 must be replaced by Figure 6C.  
The replacement has been done as indicated by the referee. 
-There is no any text in this section referring to Figure 6E. 
It is an error, as Figure 6E corresponds to the levels of acetylated ChREBP protein in liver 
samples from control and 14-day fructose-supplemented rats, but in the text it was cited as 4E. 
This error has been corrected in the new version of the manuscript (pg 19, ln 1). 
Discussion 
-In general, the Discussion is difficult to follow. It needs to be revised in a way that can be more 
interactive and clear. Perhaps an addition of a diagram would be helpful.  
According to the referee’s suggestion, we have revised the discussion and added a figure (new 
Figure 7) to make it easier to follow. 
-In the first paragraph, the authors stated that "Here, we demonstrate that fructose inhibits 
liver fatty acid <beta>-oxidation by reducing PPAR<alpha> expression and activity, mainly by 
decreasing the expression and activity of SIRT1." 
Please be more précised as this was shown only after 14-day fructose supplementation.   
We have modified the sentence, and added some discussion on fructose effects at 7 days (pg 
16, ln 18-20) of the new version of the manuscript).  
-Page 16: Please rephrase following statement: "Thus, we were disappointed that fructose 
incubation of FaO cells, despite reducing PPAR<alpha> expression, did not reduce SIRT1 and 
NAMPT. 
We have rephrased the sentence as: “However, fructose incubation of FaO cells, despite 
reducing PPARα expression, did not reduce SIRT1 and NAMPT” 
-Page 16: It is not clear to me as how a short incubation period of FaO cell with fructose is not 
sufficient to repress the SIRT1 expression, but reduces its deacetylase activity strongly enough 
to reduce the expression of PPAR<alpha>. In addition, a question arises as how long incubation 
of FaO cells with fructose could be sufficient to repress the SIRT1 expression? 
Our data shows that fructose at high concentrations directly or indirectly inhibits SIRT1 activity 
without modifying SIRT1 expression. We don’t know how much time would be necessary to 
modify SIRT1 expression, but we could not extend incubation times for longer than 48 h in FaO 
cells. 
-Page 17: The author stated that "we also found an increased amount of acetylated-ChREBP 
protein in livers of 14-day fructose-supplemented rats (Figure 4E)".  
I assume the right figure for the above statement is 6E and not 4E. 4E should be replaced by 6E. 
Yes, the referee is right; we have replaced 4E by 6E in the new version of the manuscript. 
-Page 17: The authors concluded that “In conclusion, fructose depresses PPAR<alpha> 
expression and activity, and thus fatty acid <beta>-oxidation, in rat liver cells and human 
hepatocytes by a mechanism involving a reduction of SIRT1 expression and activity”  
The decreased of PPAR<alpha> expression and activity was observed after 14 days fructose 
supplementation and a reduction of SIRT1 was not observed in rat liver cells. Please revise the 
above statement to reflect the observations accordingly. 
According to the referee’s suggestion, we have revised this final statement and reformulated it 
to reflect more precisely the main conclusions of our study: “In conclusion, fructose depresses 
PPAR<alpha> expression and activity, in hepatic tissue from 14-days fructose-supplemented 
rats and in rat and human liver cells, by a mechanism that could involve a concerted increase 
in ChREBP and a reduction of SIRT1 expression and activity." This has been included in the new 
version of the manuscript (Discussion, pg 19, last paragraph). 
Highlights 
 
. Fructose reduces PPAR expression and activity in vivo and in rat and human 
liver cells 
. Fructose effect on PPAR is not related to an increased protein-phosphatase 
A2 activity 
. Fructose reduces liver expression and activity of sirtuin 1 deacetylase 
. Increased liver content of acetylated PGC 1 could be responsible for 
fructose-mediated effects on PPAR
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Abstract: 
 
Fructose ingestion is associated with the production of hepatic steatosis and 
hypertriglyceridaemia. For fructose to attain these effects in rats, simultaneous 
induction of fatty acid synthesis and inhibition of fatty acid oxidation is required. 
We aimed to determine the mechanism involved in the inhibition of fatty acid 
oxidation by fructose and whether this effect occurs also in human liver cells. 
Female rats were supplemented or not with liquid fructose (10% w/v) for 7 or 14 
days; rat (FaO) and human (HepG2) hepatoma cells, and human hepatocytes 
were incubated with fructose 25 mM for 24 hours. The expression and activity of 
the enzymes and transcription factors relating to fatty acid -oxidation were 
evaluated. Fructose inhibited the activity of fatty acid -oxidation only in livers of 
14-day fructose-supplemented rats, as well as the expression and activity of  
peroxisome proliferator activated receptor (PPAR). Similar results were 
observed in FaO and HepG2 cells and human hepatocytes. PPAR 
downregulation was not due to an osmotic effect or to an increase in protein-
phosphatase 2A activity caused by fructose. Rather, it was related to increased 
content in liver of inactive, acetylated peroxisome proliferator activated receptor 
gamma coactivator 1, due to a reduction in sirtuin 1 expression and activity. In 
conclusion, fructose inhibits liver fatty acid oxidation by reducing PPAR 
expression and activity, both in rat and human liver cells, by a mechanism 
involving sirtuin 1 down-regulation.  
 
Key words: PPAR, steatosis, triglycerides, ChREBP 
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Abbreviations: ACO, acyl-CoA oxydase; AMPK, AMP-activated protein kinase;  
APRT, adenosyl phosphoribosyl transferase); ACC, acetyl-CoA carboxylase); 
ChREBP, carbohydrate response element binding protein; CYP4A1, 
cytochrome P450 4A1; FAS, fatty acid synthase; Foxa2, forkhead box protein 
A2; GK, glucokinase; GPAT1; glycerol phosphate acyltransferase 1; HNF4, 
hepatic nuclear factor 4; L-CPT-I, liver carnitinepalmitoyl-CoA transferase I; L-
PK, liver-pyruvate kinase; NAMPT, nicotinamide phosphoribosyltransferase; 
PGC-1peroxisome proliferator activated receptor gamma coactivator  1 
PP2A, protein phosphatase 2 A; PPAR peroxisome proliferator activated 
receptor  SCD1, stearoyl-CoA desaturase 1; SIRT1, sirtuin 1; SREBP1, sterol 
response element binding protein 1; T2DM, type 2 diabetes mellitus; Trib-3, 
mammalian tribbles homolog-3; TSA, trichostatin A. 
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1. Introduction 
 
There is a world-wide pandemic of human diseases, such as obesity, 
related to an unbalanced energy intake. Further, the International Diabetic 
Federation projects 380 million adults suffering type-2 diabetes mellitus (T2DM) 
by the year 2025 [1]. There is also increased prevalence of risk factors for 
obesity and T2DM, such as hepatic steatosis [2] and hypertriglyceridaemia [3]. 
Epidemiological evidence suggests a causal association with the 
consumption of sugar-sweetened beverages by human populations [1,4]; 
fructose is used as a sweetener in liquid beverages [1,4,5]. High energy intake, 
lack of adequate energy compensation and the special metabolism of fructose 
have been reported as reasons to explain this association [1,5]. Fructose 
ingestion is also associated with the production of hypertriglyceridemia [6] and 
hepatic steatosis [7]. 
  In vitro studies suggest that fructose directly inhibits the oxidation of fatty 
acids in rat liver mitochondria [8]. We showed, in a rat model of liquid-sugar 
feeding, that to induce hypertriglyceridemia and hepatic steatosis, a 
simultaneous induction of fatty acid synthesis and inhibition of fatty acid β-
oxidation is required [9,10]. The reduction in the activity of the hepatic fatty acid 
β-oxidation system by fructose correlated with a decrease in the expression and 
activity of peroxisome proliferator–activated receptor α (PPARα), a nuclear 
receptor that plays a key role in the transcriptional control of genes encoding 
fatty acid β-oxidation enzymes [9, 10].Fructose, but not glucose, despite the 
latter’s being ingested in identical quantity, was the only sugar able to induce 
these changes [9]. The mechanisms by which fructose inhibits the PPARα 
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system are not fully elucidated. Recently, Ravnskjaer et al. proposed that 
glucose inhibits PPARα in pancreatic cells by activating protein phosphatase 2 
A (PP2A) [11]. PP2A is also activated by other carbohydrates, such as fructose, 
through a common metabolite, xylulose-5-phosphate [10]. 
  Sirtuin 1 (SIRT1) is a NAD+-dependent deacetylase that modulates the 
functions of many proteins involved in the process of ageing and metabolic 
disorders. SIRT1 is activated by caloric restriction and selective drug activators 
[12,13]. Feige et al. [14] demonstrated that activation of SIRT1 in skeletal 
muscle and liver enhanced fatty acid oxidation, protecting from diet-induced 
fatty liver, obesity and insulin-resistance. The aim of our study was to 
investigate the effect of fructose supplementation on female Sprague-Dawley 
rats, rat (FaO) and human (HepG2) hepatoma cells and human hepatocytes. 
We examined liver transcription factors and enzymes controlling PPARα and 
fatty acid oxidation, including SIRT1 expression and activity.  
 
2. Material and methods 
 
2.1. Animals and experimental design 
 
Female Sprague-Dawley rats (Charles River, Barcelona, Spain), were 
maintained at constant humidity and temperature, with a light/dark cycle of 12 
hours, and had ad libitum access to water and to a regular diet (calories from fat 
18%, from protein 24% and from carbohydrate 58%, cat. 2018, Harlan Teklad). 
Rats were randomly assigned to a control group and a fructose-supplemented 
group (8 and 12 rats per group, respectively). Fructose was supplied as a 10% 
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(weight/volume) solution in drinking water for 7 and 14 days. Then, food and 
fructose were removed at 8 a.m. and the animals were killed by decapitation 
under isoflurane anesthesia at 10 a.m. To reduce variability in plasma 
oestrogen concentrations, female rats were killed during the diestrus period.  
Blood and liver tissue samples were collected and stored as described 
elsewhere [9]. All procedures were conducted in accordance with the guidelines 
established by the University of Barcelona's Bioethics Committee (Autonomous 
Government of Catalonia’s Act 5/1995, July 21). 
 
2.2. Cell culture 
 
 Rat hepatoma FaO cells from the European Collection of Cell Cultures 
(ECACC) were cultured in low-glucose DMEM (Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% foetal bovine serum (FBS Gold, PAA) and antibiotics 
(100 U/mL penicillin and 100 µg/mL streptomycin, Invitrogen). At 80% 
confluence, serum was reduced to 1%. Cells were incubated in the absence or 
presence of fructose, glucose or mannitol (Sigma-Aldrich, Madrid, Spain) at 25 
mM for 24 hours [10]. Human hepatoma HepG2 cells from the EuCellBank 
(Barcelona, Spain) were cultured as FaO cells. Human hepatocytes (Ready 
HepsTM Fresh Hepatocytes) were from Lonza (Basel, Switzerland). They were 
cultured and treated in HMMTM medium (Hepatocyte Medium Maintenance 
System from Lonza). In some experiments, 100 µM of Wy-14643, a PPARα 
agonist (Sigma-Aldrich, Madrid, Spain), and 20 nM of Okadaic acid, a potent 
inhibitor of PP2A phosphatase, (Sigma-Aldrich, Madrid, Spain) were added 3 
hours and 30 minutes, respectively, before fructose. 100 nM of the specific 
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SIRT-1 activator SRT1720 (Cayman Chemical, Ann Arbor, MI, USA) was added 
to the medium 12 hours after fructose supplementation. 
 
2.3. Sample preparations 
 
Total and nuclear extracts from rat liver and cells were isolated by the 
Helenius method [15]. Protein concentrations were determined by the Bradford 
method [16].  
 
2.4. Lipids and Leptin analysis  
 
Plasma triglycerides were measured by the Triglyceride L-Q test 
(Spinreact, Girona, Spain).  Plasma leptin was determined with the RL-83K RIA 
kit (Millipore, Bedford, MA, USA). Liver triglycerides were extracted and 
measured as described by Roglans et al. [17].   
 
2.5. Enzyme activity assays 
 
Hepatic fatty acid ß-oxidation activity was determined in rat livers, as in 
[18], with 30 µg of postnuclear supernatant. PP2A activity in FaO cells was 
determined by the colorimetric kit Sensolyte pNPP Protein Phosphatase Assay 
Kit (AnaSpec, Fremont, CA, USA). A co-immunoprecipitation, using 100 µg of 
total protein and 4 µg of anti-PP2A antibody (Millipore, Bedford, MA, USA), was 
conducted to purify the PP2A protein. SIRT1 activity was analyzed in FaO cells 
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by the HDAC Fluorimetric Cellular Activity Assay (BML-AK503, Enzo Life 
Sciences, Ann Arbor, MI, USA). To evaluate SIRT-1 activity selectively, TSA 
(trichostatin A, 1µM, 12h) was used as a non-sirtuin deacetylase inhibitor. 
 
2.6. RNA preparation and analysis 
 
Total RNA was isolated by using the TrizolR reagent (Invitrogen, 
Carlsbad, CA, USA). Specific mRNAs were assessed by reverse transcription 
polymerase chain reaction (RT-PCR) [17]. As internal control, adenosyl 
phosphoribosyl transferase (APRT) was used for samples from 14-day fructose-
supplemented rats and FaO cells and 18s was used for HepG2, human 
hepatocytes and 7-day fructose-supplemented rats. The number of cycles, 
primer sequences, and resulting PCR products are listed in Supplementary 
Table 1. The mRNA levels were always expressed as the ratio to APRT or 18s 
mRNA levels.  
 
 2.7. Western blot analysis  
 
 Total and nuclear proteins (10 to 30 µg from rat livers and 10 to 20 µg 
from cells) were subjected to SDS-polyacrylamide gel electrophoresis [9,10]. 
Proteins were then transferred to Immobilon polyvinylidene diflouride transfer 
membranes (Millipore, Bedford, MA) and blocked for 1 hour at room 
temperature with 5% non-fat milk solution in TBS-0.1% Tween-20. Membranes 
were then incubated with the primary polyclonal antibody raised against ACC 
(dilution 1:1,000), ChREBP, Foxa2, HNF4 and NAMPT (dilution 1:500), PP2Ac, 
 9 
PPARα (dilution 1:1,000), SIRT1 (dilution 1:500) and SREBP-1c (dilution 
1:200). Incubations with primary antibodies were performed in TBS–
0.1%Tween-20 with 5% non-fat milk (except for ACC, NAMPT and PP2Ac 
determination, which used 5% bovine serum albumin) at 4°C overnight. After 
several washes, they were incubated with horseradish peroxidase–conjugated 
anti-rabbit IgG or anti-goat IgG (1:3,000 dilution) for ChREBP determination. 
Detection was achieved using the ECL chemiluminescence kit for horseradish 
peroxidase (Amersham Biosciences). The size of detected proteins was 
estimated using protein molecular-mass standards (Invitrogen, Life 
Technologies). Antibodies were from Santa Cruz Biotechnologies (Dallas, 
Texas, USA), except those for phospho- and total ACC which were from Cell 
Signaling (Danvers, MA, USA) and PPAR from AbCam (Cambridge, UK).  
 
 2.8. Co-immunoprecipitation 
 
100 µg of nuclear extracts from rat livers were incubated with 4 μg of 
anti-acetylated-lysine antibody in a final volume of 0.5 mL with buffer containing 
10 mM PBS and 2% BSA for 4 h at 4 °C.  Immunocomplexes were captured by 
incubating with protein A/G Plus-agarose suspension (Santa Cruz 
Biotechnology) overnight at 4°C on a rocker platform. Beads were collected by 
centrifugation at 1000xg for 5 min. and washed three times with PBS-containing 
protease, deacetylase and phosphatase inhibitors. After microcentrifugation, the 
pellet was resuspended with 40 μl of SDS-PAGE sample buffer and boiled for 5 
min at 100°C. The supernatant was electrophoresed on 8% SDS-PAGE and 
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immunoblotted with an antibody against ChREBP (Santa Cruz Biotechnologies) 
and PGC-1 (Cayman).  
 2.9. Electrophoretic mobility shift assays (EMSA)  
 
 8 µg of nuclear extracts from FaO cells and rat livers were incubated with 
a PPRE-L-CPT-I probe obtained from the annealing of single-stranded 
complementary oligonucleotides spanning nucleotides –266 to -290 of the rat L-
CPT-I gene (5’-AGTACGGGCATGGAGCAAAGAGCT-3’), exactly as described 
elsewhere [19]. 
 
 2.10. Histological studies 
 
 Lipid accumulation, necrosis and fibrosis were analyzed in liver sections 
stained with Oil Red O, haematoxylin-eosin and trichromic acid, respectively. 
Images, acquired with an Olympus BX43 microscope, were interpreted at 
BioBanc (Banc de tumors-IDIBAPS, Barcelona Spain). 
 
2.11. Statistics 
 
The results are expressed as the mean of n values  standard deviation.  
Plasma samples were assayed in duplicate. Significant differences were 
established by the unpaired t-test or the one-way ANOVA test, with analysis 
afterwards (GraphPad Software V2.03). When the number of samples was too 
small or variance was not homogeneous, a non-parametric test was performed. 
The level of statistical significance was set at P ≤ 0.05. 
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3. Results  
 
3.1. Fourteen-day fructose supplementation to rats is necessary to induce 
fatty liver and hypertriglyceridaemia. Fructose-supplemented rats drank 
more liquid, reducing their ingestion of solid food (x0.78-fold). The induction of 
liver fructokinase, which controls the amount of fructose metabolized by cells 
[20], was the same at 7 and 14 days (x2.0-fold). Thus, rats increased their 
calorie intake in a similar way from 726.4 to 904.4 kcal/7days/2 rats (increase of 
1.24-fold) and from 1609.6 to 2052.4 kcal/14days/2 rats (x1.27-fold), at 7 and 
14 days, respectively. The increase was mainly due to calories obtained from 
fructose, which represented a 37 and 39% of the total calories consumed at 7 
and 14 days, respectively. This increase was not compensated by a sufficient 
reduction in the ingestion of solid food. Visceral adipose tissue and body weight 
were not modified (Table 1). Despite this, only 14-day fructose-supplemented 
rats increased their percentage of liver weight (x1.2-fold), liver triglycerides 
(x1.9-fold), plasma triglycerides (x1.5-fold) and adiponectin levels (x1.7-fold) 
with unmodified plasma leptin levels (Table 1). While no clear signs of necrosis 
or fibrosis were detected, liver steatosis was confirmed by histological analysis 
(Figure 1). Thus, we proceeded to determine liver fatty acid synthesis and liver 
fatty acid -oxidation in livers of female fructose-supplemented rats.  
 
3.2. Seven days of fructose supplementation suffices to increase the 
expression of markers of liver fatty acid synthesis. Fructose similarly 
increased the liver expression of carbohydrate response element binding 
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protein (ChREBP) and its target genes related to fatty acid synthesis [21] liver-
pyruvate kinase (L-PK), fatty acid synthase (FAS), stearoyl-CoA desaturase 
(SCD1), glycerol phosphate acyltransferase 1 (GPAT1), acetyl-CoA 
carboxylase (ACC), and elongation of very long chain fatty acids family member 
6 (Elovl6), after 7- and 14-day supplementation (Table 2). As we showed 
elsewhere [10,20], the expression of the mature form of sterol response 
element binding protein 1 (SREBP1) and its target gene glucokinase (GK) [22], 
was not modified (Table 2).  
 
3.3. Fructose induces a bimodal change in the expression and activity of 
PPAR and its target genes. Liver PPAR expression increased after 7-day 
supplementation of fructose to rats, while after 14 days, its expression was 
repressed x0.75-fold (Table 3). The expression of PPAR target genes, such as 
liver-carnitinepalmitoyl-CoA transferase-I (L-CPT-I), acyl-CoA oxidase (ACO), 
and the mammalian tribbles homolog-3 (Trib-3) [23,24], followed a similar 
pattern (Table 3), pointing to a similar bimodal change (increase-decrease) in 
the activity of PPAR. In accordance, the specific retention bands produced 
after incubation of liver nuclear extracts with an oligonucleotide reproducing the 
peroxisome proliferator response element (PPRE) of rat L-CPT-I showed a 
similar change in intensity after 7- and 14-day fructose supplementation (Figure 
2A).  On the other hand, the expression of total and phosphorylated AMP-
activated protein kinase (AMPK), an enzyme which increases fatty acid 
oxidation in hepatic cells, was not modified (Table 3). 
  Surprisingly, the activity of the liver fatty acid -oxidation system, under 
the transcriptional control of PPARα [25], was similarly reduced x0.55-fold after 
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7- and 14-day fructose supplementation (Figure 2B). To investigate the 
mechanisms by which fructose inhibits fatty acid -oxidation, despite opposite 
changes in PPAR, we assessed the phosphorylation of ACC. Our results 
showed increased expression of total and phosphorylated ACC at both 7 and 14 
days (Table 2), implying increased production of malonyl-CoA, a known 
allosteric inhibitor of L-CPT-I that controls the whole fatty acid -oxidation 
system [26]. On the other hand, we assessed the expression of the regulator of 
G protein signaling 16 (RGS16), a physiological inhibitor of the fatty -oxidation 
system [27]. Livers of 7- and 14-day fructose supplemented rats had increased 
expression of RGS16 (Figure 2C), but the protein expression was not modified 
at any time (Figure 2D).  
To avoid variability in response due to fluctuations in the amount of sugar 
ingested in the in vivo studies, we assessed the PPARsystem after the 
incubation of rat liver cells with fructose. 
 
3.4. Fructose represses PPAR expression and activity in liver cells from 
rat and human origin. FaO rat hepatoma cells incubated for 24 hours with 
fructose 25 mM showed a reduction in the expression of PPAR and two of its 
target genes, ACO and cytochrome P450 4A1 (CYP4A1) (Figure 3A-1C). This 
was not produced by an osmotic shock, as a similar concentration of mannitol 
induced no change in the expression of these genes (Figure 3A-1C), and was 
specific to fructose, as glucose induced no significant changes (Figure 3A-1C), 
in accordance with our previous results in vivo [9]. 
 As the production of PPAR ligands is probably minimal in cultured cells, 
we assessed the effect of fructose in the presence of Wy-14,643, a potent and 
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specific PPAR ligand [28]. 25 mM fructose incubation for 24 hours significantly 
reduced the induction of L-CPT-I, ACO and CYP4A1 elicited by Wy-14,643 
(Figure 3D-1F). When we assayed the specific binding of FaO cell nuclear 
extracts to an oligonucleotide reproducing the PPRE of rat L-CPT-I, we 
observed a major band whose intensity was depressed in the presence of Wy-
14,643 and further increased in the presence of fructose (Figure 3G). In naïve 
FaO cells, the PPRE in the L-CPT-I promoter is mainly occupied by an 
unproductive protein complex that drops in the presence of Wy-14,643, favoring 
the expression of L-CPT-I, and increases further on co-incubation with fructose, 
thus reducing the expression of L-CPT-I. 
  To determine whether fructose had similar effects in human cells, we 
incubated human HepG2 hepatoma cells and normal human hepatocytes for 24 
hours with fructose 25 mM. Fructose reduced the expression of PPARand L-
CPT-I in the presence and in the absence of Wy-14,643 in these human liver 
cells, implying a similar effect of fructose on PPAR in rats and humans (Figure 
4). 
 
3.5. Protein Phosphatase 2A (PP2A) activity is not involved in the 
reduction of PPAR expression and activity by fructose. ChREBP 
dephosphorylated by PP2A is retained in the nucleus, increasing the 
transcription of its target genes, such as L-PK or RGS16 [21]. Sustained 
activation of PP2A by fructose could be responsible, through ChREBP 
activation, for the reduced expression and activity of PPAROnly livers from 
14-day fructose-supplemented rats showed an increase in the ChREBP protein 
(x2.01-fold) and in the catalytic subunit of PP2A (x1.28-fold) (Table 2). To test 
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this hypothesis, we determined the effect of fructose on these parameters in 
FaO cells. 
  Incubation of FaO cells with 25 mM fructose for 24 hours increased the 
expression and activity of PP2A and ChREBP (Figure 5A-B). Only fructose, but 
not glucose, was able to induce significantly the expression of L-PK (x2.06-fold), 
a prototypical ChREBP-driven gene, in FaO cells (Figure 5E). When FaO cells 
were incubated with okadaic acid, a known inhibitor of PP2A [29], although the 
fructose-induced increase in PP2A activity was blunted, the effect of fructose on 
ChREBP, L-PK and PPAR was preserved (Figure 5A-D).  
 
3.6. Fructose supplementation reduces liver SIRT1 expression and 
activity. The liver expression of hepatic nuclear factor 4 (HNF4), a transcription 
factor also controlling the expression of L-CPT-I [30], paralleled that of PPAR. 
The expression of forkhead box protein A2 (Foxa2) [31], a transcription factor 
regulating fatty acid oxidation, was reduced only after 14-day fructose 
supplementation (x0.79 fold) (Table 3).  
  We found only in livers of 14-day fructose-supplemented rats a reduction 
in SIRT1 (x0.36-fold, Figure 6A) and nicotinamide phosphoribosyltransferase 
(NAMPT, x0.73-fold, Figure 6B), an enzyme essential for the synthesis of NAD+, 
suggesting a deficit of SIRT1 activity, which could be responsible for the 
reduction in the expression and activity of the PPAR system.  
  Although in FaO cells incubation with 25 mM fructose for 24 hours did not 
modify the expression and activity of SIRT1 and NAMPT (data not shown), 
fructose was also able to efficiently block the increase in PPAR expression 
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induced by incubating FaO cells with SRT1720, a potent and selective activator 
of SIRT1 [32] (Figure 6C). 
  To confirm the reduction of SIRT1 activity in vivo by fructose, we 
determined the amount of the acetylated form of a well-known substrate of 
SIRT1 activity, peroxisome proliferator activated receptor coactivator 1 (PGC-
1) [13]. The amount of acetylated-PGC-1 was clearly increased in livers of 
14-day fructose-supplemented rats (Figure 6D). 
 
4. Discussion  
 
  We showed that hypertriglyceridaemia and fatty liver after carbohydrate 
ingestion in rats results from simultaneous induction of liver fatty acid synthesis 
and inhibition of fatty acid oxidation [9,10,20]. Simple sugars induce lipid 
synthesis, but only fructose, at least in rats, inhibits liver fatty acid oxidation.  
Here, we demonstrate that fructose inhibits hepatic fatty acid oxidation at both 7 
and 14 days of supplementation (10% w/v) but through different mechanisms, 
involving the reduction of PPARα expression only at the latter time-point. In fact, 
at 7 days fructose supplementation increases PPARα expression and activity, 
and the reduction in fatty acid β-oxidation may be related to increased ACC 
expression leading to the production of malonyl-CoA and to CPT-1 inhibition. 
On the contrary, fructose supplementation for 14 days inhibits liver fatty acid -
oxidation also by reducing PPAR expression and activity, mainly by 
decreasing the expression and activity of SIRT1. This fructose-related inhibition 
of PPARis reproduced in human HepG2 hepatoma cells and in human 
hepatocytes.  
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  Activation of SIRT1 protects against diet-induced metabolic disorders by 
enhancing fatty acid oxidation [14]. This effect could be mediated by two 
complementary mechanisms: 1. Activation of AMPK [33], which we can rule out 
from our present results, and 2. deacetylation and activation of PGC-1[3], a 
cofactor of PPAR necessary for the transcriptional control of genes related to 
fatty acid oxidation [35]. Conversely, hepatocyte-specific deletion of SIRT1 
impairs PPAR signaling and decreases fatty acid -oxidation [36]. We showed 
that there was a reduction in SIRT1 expression, as well as in nicotinamide 
phosphorybosyl-transferase (NAMPT), the rate-limiting enzyme in NAD+ 
biosynthesis [37], pointing to a decrease in SIRT1 activity in the livers of 14-day 
fructose-supplemented rats. Consistently, a well-known substrate of SIRT-1, 
PGC-1, remained hyperacetylated in the same samples. The inactivity of 
acetylated PGC-1 could be responsible for the reduced expression and activity 
of PPAR and the fatty acid -oxidation system. However, fructose incubation 
of FaO cells, despite reducing PPARexpression, did not reduce SIRT1 and 
NAMPT. Nevertheless, FaO cells were incubated with fructose for 24 hours, in 
comparison with the 14-day fructose supplementation in rats. Moreover, the 
fluorimetric assay used to detect SIRT1 is designed for evaluation of total 
deacetylase activity and not specifically the SIRT1 activity present in a complex 
cellular mixture. Thus, it is relevant that the incubation of FaO cells with a 
SIRT1 agonist, SRT1720 [14], increased PPAR expression, an effect that was 
blunted by fructose. In FaO cells, a short incubation period with fructose is not 
sufficient to repress the expression of SIRT1, but probably reduces its 
deacetylase activity strongly enough to reduce the expression of PPAR.  
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  The mechanism involved in the fructose-mediated reduction of SIRT1 
expression remains to be determined. Our results suggest ChREBP as a 
potential candidate. It has been previously suggested that ChREBP is activated 
by fructose-induced PP2A activity. Previous work by Dentin et al [38] and our 
present data suggest that this is not the case, given that in our in vitro studies 
OA inhibited PP2A activity without changing the effect of fructose on target 
genes. It has also been suggested that ChREBP indirectly represses the liver 
expression of PPAR-target genes through the increased expression of RGS16 
[27]. However, although we observed increased mRNA levels of RGS16 in 
fructose-fed rats, protein levels were not modified by the treatment, suggesting 
that the effects of fructose on genes controlled by PPARα is independent from 
RGS16.  Moreover, Boergesen et al. [39] showed that glucose reduces PPAR 
expression in pancreatic -cells, but not in rat hepatoma FaO cells, by activating 
ChREBP. We found that glucose does not increase the expression of the l-pk 
gene in FaO cells (Figure 5E), suggesting a lack of ChREBP activation. On the 
contrary, fructose efficiently increased the expression of the l-pk gene in FaO 
cells and human hepatocytes (Figure 4C), as well as reducing PPAR 
expression in these cells. Indeed, recent research by Noriega et al. [40] has 
shown that ChREBP does repress SIRT1 expression. Conversely, liver-specific 
knock-out of SIRT1 increases ChREBP, promoting steatosis [41]. Thus, 
fructose could impair PPAR expression and activity by activating ChREBP, 
which could be responsible for the direct increase in the expression of lipogenic 
genes, as well as, indirectly by repressing SIRT1, for the reduction of fatty acid 
oxidation in liver. Although there is no data suggesting ChREBP as a SIRT1 
substrate, we also found an increased amount of acetylated-ChREBP protein in 
 19 
livers of 14-day fructose-supplemented rats (Figure 6E). Sustained consumption 
of fructose could generate a feed-forward cycle, as the transcriptional activity of 
acetylated ChREBP is higher, at least in lipogenic target-genes, than the 
corresponding activity of the deaceylated form [42]. A diagram of the proposed 
involvement of SIRT1 as a key molecule in the production of fructose-related 
effects on lipid synthesis and fatty acid oxidation is shown in Figure 7. 
    The fructose-mediated reduction in liver PPAR expression and activity 
is reproduced in human hepatocytes, probably by a SIRT1-related mechanism, 
suggesting that a similar reduction in hepatic fatty acid oxidation could be 
present in humans consuming fructose-sweetened beverages. In fact, a 
fructose-rich diet reduces liver fatty acid oxidation in healthy male subjects [43]. 
Patients suffering from metabolic alterations (metabolic syndrome, T2DM) are 
frequently treated with fibrate-type hypolipidemic drugs, whose pharmacological 
properties are due to PPAR activation [28]. Our results suggest that 
consumption of fructose-sweetened beverages by this population could reduce 
the efficacy of drug-therapy, worsening their metabolic control.   
  In conclusion, fructose depresses PPAR expression and activity in 
hepatic tissue from 14-days fructose-supplemented rats, and in rat and human 
liver cells, by a mechanism that could involve a concerted increase in ChREBP 
and a reduction of SIRT1 expression and activity. The possible role of ChREBP 
activation, as the key molecular switch for the production of the two main effects 
of fructose in liver, increased lipid synthesis and decreased fatty acid oxidation, 
deserves further studies.  
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Figure Legends 
 
Figure 1. Histological study of liver sections from control and 14-day 
fructose-supplemented rats: Livers were cryosectioned and processed for 
histological examination of inflammation, collagen deposition and fat infiltration. 
Images are representative of liver sections from control (n = 4) and fructose-
supplemented rats (n = 4) stained with H&E (A),  trichrome Masson (B) and oil 
red O (C). 
 
Figure 2. In vivo effect of fructose on rat liver binding to a PPRE 
oligonucleotide, fatty acid -oxidation activity and RGS16 expression: (A) 
Representative EMSA autoradiography showing the binding of pooled nuclear 
extracts (NE) from control (n=4) and fructose-supplemented rats (n=6) to a 
PPRE oligonucleotide. (B)  Fatty acid β-oxidation activity, expressed as nmols 
of oxidized palmitoyl-CoA/min/mg of protein in liver postnuclear supernatant, in 
control (n=4) and fructose-supplemented (n=6) rats. (C) mRNA of RGS16 in 
control and fructose-supplemented rats. Each bar represents the mean±sd of 
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values obtained from n=4 and n=5 animals (for control and fructose groups, 
respectively). The autoradiography above the figure shows the bands 
corresponding to Rsg16 mRNA and that of the aprt gene, used as an internal 
control in the PCR reaction to normalize the results, from liver samples of 3 
animals from each treatment group. (D) Bar plot showing the levels of RSG16 
protein in hepatic samples from control and fructose-supplemented rats. Each 
bar represents the mean±sd of values obtained from n=4 and n=5 animals (for 
control and fructose groups, respectively). Above the figure, a representative 
Western blot shows the RSG16 bands corresponding to 3 different control and 
fructose-fed rats.* p<0.05; ** p<0.01 
 
Figure 3. Fructose represses PPAR expression and activity in FaO rat 
hepatoma cells: The mRNA levels of PPAR α (A), ACO (B, D), CYP4A1(C,F) 
and L-CPT-I (E) in control (CT) or in FaO cells cultured with 25 mM fructose 
(FRC), 25 mM glucose (GLC), 25 mM mannitol, 100 µM Wy-14.643 or fructose 
plus Wy-14.643 for 24 hours. Each bar represents the mean±sd of three 
different assays performed in duplicate. (G) Representative EMSA 
autoradiography showing the binding of nuclear extracts (NE) from control, Wy-
14.643 and Wy-14.643 plus fructose-treated FaO cells to a PPRE 
oligonucleotide.* p<0.05; ** p<0.01 
 
Figure 4. Fructose represses PPAR expression and activity in human 
liver cells: mRNA of PPAR(A)L-CPT-I (B) and L-PKC) in human 
hepatocytes, and L-CPT-I (D) in HepG2 cells in control cells (CT) or in cells 
treated with fructose (FRC), Wy-14.643, or fructose plus Wy-14.643. Each bar 
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represents the mean±sd of three different assays performed in duplicate. * 
p<0.05; ** p<0.01 
 
Figure 5. Protein Phosphatase 2A (PP2A) activity is not involved in the 
reduction of PPAR expression and activity by fructose:  (A) PP2A activity, 
ChREBP protein (B) and L-PK (C) and PPARα (D) mRNA in FaO cells 
incubated in the absence (CT) or in the presence of 25 mM fructose (FRC), 20 
nM okadaic acid (OkA) or 25 mM fructose plus 20 nM okadaic acid (F+OkA) for 
24 h. (E) mRNA of L-PK in control cells (CT) or in cells treated with 25 mM 
fructose (FRC) or 25 mM glucose (GLC) for 24 hours. Each bar represents the 
mean±sd of three different assays performed in duplicate.  **p<0.01, ***p<0.001 
vs CT; #p<0.01 vs FRC.  
 
Figure 6. Fructose reduces liver SIRT1 expression and increases the 
amount of acetylated proteins: SIRT1 (A) and NAMPT (B) proteins in the 
livers of control and fructose-supplemented female rats. Each bar represents 
the mean±sd of values obtained from n=4 and n=5 animals (for control and 
fructose groups, respectively). Above the figure, a representative Western blot 
shows the SIRT1 and NAMPT bands corresponding to 3 different control and 
fructose-fed rats (C) mRNA of PPAR in control FaO cells (CT) or in cells 
treated with fructose (FRC), SRT1720, or fructose plus SRT1720. Each bar 
represents the mean±sd of three different assays performed in duplicate. 
Acetylated PGC1α (D) and ChREBP (E) proteins in liver samples from control 
and 14-day fructose-supplemented rats.  
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Figure 7. Fructose increases liver lipid synthesis by directly activating ChREBP 
and indirectly by inhibiting SIRT1, thus promoting the accumulation of active, 
acetylated-ChREBP. Further, inhibition of SIRT1 also promotes the 
accumulation of inactive, acetylated-PGC1, reducing the expression and 
activity of PPAR and its target genes controlling liver fatty acid oxidation. 
 
 
 
 
 
 
 
Table 1. Fructose effects on líquid and food ingestion, triglyceride and leptin plasma analytes, liver triglycerides and 
body and tissue weight values and fructokinase protein levels at 7 and 14 days.  
 
          7 Days                                                                 14 Days 
 
 Control (n = 4) Fructose (n = 6) Control (n = 4) Fructose (n = 6) 
 
AUC ingested líquid 
 (ml/days/2 rats) 
 
 
360 ± 8 
 
845 ± 198* 
 
706 ± 91 
 
1995 ± 430* 
AUC consumed diet 
(g/days/2 rats) 
 
227 ± 2 177 ± 13** 503 ± 12 392 ± 44* 
AUC body weight 
(g/days/rat) 
1478 ± 53 1495 ± 94 3575 ± 380 3687± 257 
     
Final body weight (g) 249.5 ± 7.0 257.0 ± 19.4 263.7 ± 25.9 276.7 ± 20.7 
     
Adipose tissue weight 
(g) 
1.49 ± 0.69 1.53 ± 0.69 1.92 ± 1.24 2.57 ± 1.05 
     
% liver weight  
 
3.5 ± 0.2 3.5 ± 0.3 3.2 ± 0.2 3.8 ± 0.2** 
FK protein  (a.u.) 
 
1 ± 0.32 1.78 ± 0.28** 1 ± 0.17 2.18 ± 0.20** 
Hepatic Triglycerides 
(mg/g liver) 
 
6.8 ± 0.6 8.2 ± 3.0 4.1 ± 2.3 7.7 ± 2.4* 
Plasma Triglycerides 
(mg/dl) 
 
58 ± 27 57 ± 13 63 ± 12 94 ± 17** 
Plasma Leptin (ng/ml) 
 
2 ± 1 3.2 ± 2.3 2.8 ± 2.7 4.7 ± 2.2 
Plasma Adiponectin 
(μg/ml) 
2.7 ± 0.7 3.9 ± 1.5 2.3 ± 0.7 4.0 ± 0.7* 
*P<0.05, **P<0.01 
   
Table 1
Table 2. Expression of genes / proteins involved in lipogenic pathways after 7- and 14-day fructose supplementation.  
 
 
          7 Days                                                                  14 Days 
 
Gene Control (n = 4) Fructose (n = 5) Control (n = 4) Fructose (n = 5) 
Fas 1 ± 0.20 6.28 ± 5.34** 1 ± 0.39 4.66 ± 1.52** 
Gk 1 ± 0.34 1.09 ± 0.62 1 ± 0.43 1 ± 0.46 
Gpat1 1 ± 0.26 1.57 ± 0.18** 1 ± 0.04 1.74 ± 0.81** 
L-pk 1 ± 0.29 1.59 ± 0.14** 1 ± 0.05 2.12 ± 0.64** 
Scd1 1 ± 0.52 11.98 ± 5.06** 1 ± 0.39 4.39 ± 2.53* 
Elovl6 1 ± 0.40 2.88 ± 1.47* 1 ± 0.35 5.29 ± 1.73* 
 
Protein  
    
 
p-ACC 
 
1 ± 0.25 
 
1.78 ± 0.11** 
 
1 ± 0.10 
 
1.28 ± 0.19* 
ACC 1 ± 0.27 2.01 ± 0.15** 1 ± 0.16 1.49 ± 0.36* 
ChREBP 1 ± 0.14 1.15 ± 0.23 1 ± 0.36 2.01 ± 0.87* 
PP2Ac 1 ± 0.07 0.9 ± 0.08 1 ± 0.13 1.28 ± 0.15**  
SREBP-1c  68KD 1 ± 0.12 0.80 ± 0.14 1 ± 0.24 1.12 ± 0.16 
*P<0.05, **P<0.01   
Table 2
Table 3. Expression of genes / proteins involved in fatty acid oxidation pathways after 7- and 14-day fructose 
supplementation.  
 
 
               7 Days                                                                14 Days 
 
Gene Control (n = 4) Fructose (n = 5) Control (n = 4) Fructose (n = 5) 
 
L-cpt-1 
 
1 ± 0.48 
 
1.68 ± 0.69 
 
1 ± 0.37 
 
0.56 ± 0.21* 
Aco 1 ± 0.09 1.26 ± 0.12** 1 ± 0.02 0.80 ± 0.11* 
Trib-3 1 ± 0.61 3.34 ± 0.89** 1 ± 0.25 0.65 ± 0.21* 
Ppar 1 ± 0.72 2.08 ± 0.40* 1 ± 0.27 0.36 ± 0.22** 
 
Protein  
    
 
PPAR
 
1 ± 0.50 
 
1.10 ± 0.44 
 
1 ± 0.12 
 
0.75 ± 0.16* 
p-AMPK 1 ± 0.32 1.06 ± 0.20 1 ± 0.24 0.91 ± 0.14 
AMPK 1 ± 0.34 0.98 ± 0.17 1 ± 0.28 1.28 ± 0.20 
HNF4 1 ± 0.51 1.76 ± 0.49* 1 ± 0.23 0.52 ± 0.19** 
Foxa2 1 ± 0.16 1.13 ± 0.20 1.1 ± 0.11 0.87 ± 0.12* 
 *P<0.05, **P<0.01  
Table 3
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Supplemental table 1. Primers used for the PCR reaction: A. Rat samples and FaO cells. B. Human hepatocytes (H.H.) and HepG2 
cells. 
 
 
A 
 
GenBank
TM 
nº 
 
Primer sequences  
 
PCR 
product (bp) 
 
Amplif. Cycles  
Rat / FaO 
 
18S M-100098.1 Forward: 5’-CCAAAGTCTTTGGGTTCCGGG-3’ 
Reverse: 5’-GCTCAATCTCGGGTGGCTGAA-3’ 
337 bp 18 / - 
APRT L04970 Forward: 5’-AGCTTCCCGGACTTCCCCATC-3’ 
Reverse: 5’-GACCACTTTCTGCCCCGGTTC-3’ 
329 bp 23 / 21 
ACO NM_017340 Forward: 5’-ACTATATTTGGCCAATTTTGTG-3’ 
Reverse: 5’-TGTGGCAGTGGTTTCCAAGCC-3’ 
195 bp 23 / 24 
CYP4A1 NM_175837 Forward: 5’-CTGGCTTCCTCCAAGTGGCCT-3’ 
Reverse: 5’-TTGCTTCCCCAGAACCATCGA-3’ 
509 bp - / 25 
ELOVL6 NM_ 134383 Forward: 5’-AGCCATCCAATGGTGCAGGA-3’ 
Reverse: 5’-TGCTTTGCTGAGCACAAACGC-3’ 
301 bp 22 / - 
FAS M76767 Forward: 5’-GTCTGCAGCTACCCACCCGTG-3’ 
Reverse: 5’-CTTCTCCAGGGTGGGGACCAG-3’ 
214 bp 20 / - 
GPAT1 AF021348 Forward: 5’-ATCCGCAACGCTGAAATGGAA-3’ 
Reverse: 5’-GGCAAACATGCCCTTGTGGAC-3’ 
244 bp 22 / -  
GK J04218 Forward: 5’-AGAAGGAGATGGACCGTGGCC-3’ 
Reverse: 5’-TCCCTTCTGCTCCAGCGGCCT-3’ 
421 bp 23 / - 
L-CPT-I L07736 Forward: 5’-TATGTGAGGATGCTGCTT-3’ 
Reverse: 5’-CTCGGAGAGCTAAGCTTG-3’ 
629 bp 23 / 23 
L-PK M11709 Forward: 5’-TATGGCGGACACCTTCCTGGA -3’ 
Reverse: 5’-GCTGAGTGGGGAGGTTGCAAA-3’ 
250 bp 23 / 21 
PPAR    M88592 Forward: 5’-GGCTCGGAGGGCTCTGTCATC-3’ 
Reverse: 5’-ACATGCACTGGCAGCAGTGGA-3’ 
654 bp 23 / 25 
RGS16 AY651775 Forward: 5’-CACCTGCCTGGAAAGAGCCAA-3’ 
Reverse: 5’-GGCCAGCCAGAACTCCAGGTT-3’ 
259 bp 26 / - 
SCD1 J02585 Forward: 5’-GCTCATCGCTTGTGGAGCCCAC-3’ 
Reverse: 5’-GGACCCCAGGGAAACCAGGAT-3’ 
521 bp 18 / - 
SREBP1C L16995 Forward: 5’-TCACAGATCCAGCAGGTCCCC-3’ 
Reverse: 5’-GGTCCCTCCACTCACCAGGGT-3’ 
180 bp 23 / - 
Trib3 
 
NM_144755 Forward: 5’-TGCTCTTTGGCAAGATCCGTA-3’ 
Reverse: 5’-CAACCTGGTCCATCTCCCTTC-3’ 
204 bp 26 / - 
 
B 
 
 
GenBank
TM 
nº 
 
Primer sequences  
 
PCR 
product (bp) 
 
Amplif. Cycles 
HepG2 / H.H. 
 
18S M-100098.1 Forward: 5’-CCAAAGTCTTTGGGTTCCGGG-3’ 
Reverse: 5’-GCTCAATCTCGGGTGGCTGAA-3’ 
337 bp 18 / 18 
L-CPT-I U66828 Forward: 5’-TGATCCGCATGAAGAATGGCA-3’ 
Reverse: 5’-GCGGAAGAAGAAGATGCCCGT-3’ 
274 bp 34 / 28 
L-PK M15465 Forward: 5’- AGGAGCTGGGCACTGCCTTCT-3’ 
Reverse: 5’-GTGGGAGCCGTGGGAGAAGTT-3’ 
227 bp - / 26 
PPAR    EU650667 Forward: 5’-TCTGAAGAGTTCCTGCAAGAAATGG-3’ 
Reverse: 5’-AGCATCCCGTCTTTGTTCATC-3’ 
953 bp - / 24 
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